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Gpr40 Is Expressed in Enteroendocrine Cells and
Mediates Free Fatty Acid Stimulation of Incretin
Secretion
Sara Edfalk, Pa ¨r Steneberg, and Helena Edlund
OBJECTIVE—The G-protein–coupled receptor Gpr40 is ex-
pressed in -cells where it contributes to free fatty acid (FFA)
enhancement of glucose-stimulated insulin secretion (1–4). How-
ever, other sites of Gpr40 expression, including the intestine,
have been suggested. The transcription factor IPF1/PDX1 was
recently shown to bind to an enhancer element within the
5-ﬂanking region of Gpr40 (5), implying that IPF1/PDX1 might
regulate Gpr40 expression. Here, we addressed whether 1)
Gpr40 is expressed in the intestine and 2) Ipf1/Pdx1 function is
required for Gpr40 expression.
RESEARCH DESIGN AND METHODS—In the present study,
Gpr40 expression was monitored by X-gal staining using Gpr40
reporter mice and by in situ hybridization. Ipf1/Pdx1-null and
-cell speciﬁc mutants were used to investigate whether Ipf1/
Pdx1 controls Gpr40 expression. Plasma insulin, glucose-depen-
dent insulinotropic polypeptide (GIP), glucagon-like peptide-1
(GLP-1), and glucose levels in response to acute oral fat diet were
determined in Gpr40 mutant and control mice.
RESULTS—Here, we show that Gpr40 is expressed in endo-
crine cells of the gastrointestinal tract, including cells expressing
the incretin hormones GLP-1 and GIP, and that Gpr40 mediates
FFA-stimulated incretin secretion. We also show that Ipf1/Pdx1
is required for expression of Gpr40 in -cells and endocrine cells
of the anterior gastrointestinal tract.
CONCLUSIONS—Together, our data provide evidence that
Gpr40 modulates FFA-stimulated insulin secretion from -cells
not only directly but also indirectly via regulation of incretin
secretion. Moreover, our data suggest a conserved role for
Ipf1/Pdx1 and Gpr40 in FFA-mediated secretion of hormones
that regulate glucose and overall energy homeostasis. Diabetes
57:2280–2287, 2008
M
ature -cells respond to elevated glucose
levels by secreting insulin in a tightly con-
trolled manner. The physiological response of
the -cell to elevated blood glucose levels is
critical for maintenance of normoglycemia, and impaired
glucose-stimulated insulin secretion (GSIS) is a prominent
feature of overt type 2 diabetes. Although glucose is
recognized as the major stimulator of insulin secretion
from -cells, other stimuli, such as amino acids, hormones,
and free fatty acids (FFAs), also inﬂuence insulin secre-
tion (6,7). Thus, under normal settings, insulin secretion
from -cells in response to food intake is evoked by the
collective stimuli of nutrients, such as glucose, amino
acids, and FFAs, and hormones like the incretins gluca-
gon-like peptide-1 (GLP-1) and glucose-dependent insuli-
notropic polypeptide (GIP) (6,7).
FFAs are known to inﬂuence insulin secretion from
-cells primarily by enhancing GSIS. The FFA receptor
Gpr40 is preferentially expressed in -cells and is acti-
vated by medium- to long-chain FFAs, thereby triggering a
signaling cascade that results in increased levels of [Ca
2]i
in -cell lines and subsequent stimulation of insulin secre-
tion (1,3,8). Gpr40-deﬁcient -cells secrete less insulin in
response to FFAs, providing evidence that Gpr40 mediates
part of the FFA stimulatory effect on insulin secretion
(2,4). However, loss of Gpr40 protects mice from obesity-
induced hyperglycemia, glucose intolerance, hyperinsulin-
emia, fatty liver development, increased hepatic glucose
output, and hypertriglyceridemia (2). These data provide
evidence that FFA stimulation of insulin secretion via
Gpr40 contributes to obesity-induced hyperinsulinemia,
which in turn is linked to fatty liver development and
hepatic insulin resistance.
Lipids and FFAs also stimulate the secretion of several
gut “satiety” hormones, including cholocystokinine (CCK),
GLP1, and peptide YY (PYY), and the related FFA receptor
Gpr120 has been suggested to mediate FFA-stimulated
secretion of GLP-1 from L-cells (9). In addition, stimula-
tion of the G-protein–coupled receptor Gpr119, the ligands
of which are phospholipids and fatty acid amides, have
also been shown to result in increased GLP-1 and GIP
secretion (10). RT-PCR analyses have suggested that
Gpr40 is expressed in the intestine, leaving open a poten-
tial role also for Gpr40 in FFA stimulation of gut hormones
(1,11).
The transcription factor IPF1/PDX1 is highly expressed
in -cells and controls key aspects of -cell function by
regulating the expression of genes involved in glucose
sensing, insulin gene expression, and insulin secretion
(12–14). Loss or perturbation of Ipf1/Pdx1 function in
-cells leads to impaired GSIS and consequently diabetes
or glucose intolerance in both mice and humans (12,15),
highlighting the central role for Ipf1/Pdx1 in ensuring
-cell function. Recently, IPF1/PDX1 has been shown to
bind to an enhancer element within the 5-ﬂanking region
of Gpr40 (5), implying that Ipf1/Pdx1 might regulate
Gpr40 expression in -cells and thus FFA-mediated stim-
ulation of insulin secretion.
To determine whether Gpr40 is expressed in the intes-
tine and whether Ipf1/Pdx1 function is required for Gpr40
expression, we investigated the expression of Gpr40 in
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Gpr40 is expressed in endocrine cells of gastrointestinal
tract, including cells expressing the incretin hormones
GLP-1 and GIP. We also show that Ipf1/Pdx1 is required
for Gpr40 expression in -cells and endocrine cells of the
anterior gastrointestinal tract. Moreover, we show that
secretion of GLP-1 and GIP is diminished in Gpr40-null
mutant mice. Together, these data raise the possibility that
Gpr40 modulates FFA-stimulated insulin secretion from
-cells not only directly but also indirectly via regulation
of incretin secretion.
RESEARCH DESIGN AND METHODS
The animal studies were approved by the Institutional Animal Care and Use
Committee of Umeå University and conducted in accordance with the
Guidelines for the Care and Use of Laboratory Animals. The generation of
Gpr40
/lacZ, Ipf1/Pdx1
/, and Rip1/Ipf1
 have been previously described
(2,12,16). Brieﬂy, Gpr40
/lacZ mice were generated by replacing the Gpr40
open reading frame with the lacZ gene encoding -galactosidase (-gal). In
Ipf1/Pdx1
/-null mice, exon 2, encoding the DNA-binding homeodomain,
was deleted. The Rip1/Ipf1
 mice are generated by breeding mice in which
exon 2 of the Ipf1/Pdx1 gene is ﬂanked by two loxP sites with mice where the
Cre-recombinase is under the control of Rat insulin 1 (Rip1) promoter. In the
resulting Rip1/Ipf1
 mice, exon 2 of Ipf1/Pdx1 becomes out-recombined
speciﬁcally in -cells as a consequence of Cre-recombinase expression and
activity.
Glucose, insulin, GIP, GLP-1, glucagon, FFA, and triglyceride measure-
ments. Intraperitoneal glucose tolerance tests were performed on overnight-
fasted, sedated mice essentially as previously described (2). For oral glucose
tolerance test, 300 l 20% glucose solution was administered to overnight-
fasted, sedated mice. For the acute, high-fat diet experiments, a paste was
generated by mixing 7.5 g diet D12309 (58% kcal fat content; Research Diets)
with 3 ml tap water, and 300 mg paste was then administered by oral gavage
to overnight-fasted, sedated mice. Blood glucose levels were measured using
a Glucometer Elite (Bayer), serum insulin levels were measured using ELISA
(Mercodia), and total plasma GIP and GLP-1 concentrations were determined
according to the manufacturer’s instructions for the GIP-ELISA (EZRMGIP-
55K; Linco Research) and the GLP-1-RIA (GLP1T-36HK; Linco Research) kit.
Plasma glucagon levels were determined using the Glucagon RIA kit (GL-32K;
Linco Research). FFA and triglyceride measurements were done according to
the manufacturer’s instructions using FFAs, Half-micro test (Roche), and
Accutrend GCT Triglycerides (Roche).
In situ hybridizations, X-gal staining, and immunohistochemistry. In
situ hybridization using DIG-labeled probes speciﬁc for the mouse Gpr40
transcript was carried out on embryonic day (e) 17 embryos as previously
described (2). Immunohistochemical localization of antigens, double-label
immunohistochemistry, and X-gal staining on tissues and confocal micros-
copy were carried out as previously described (2). Primary antibodies used
were rabbit anti–-gal (Cappel), chicken anti–-gal (AbCam), rabbit anti-GIP
(Peninsula), rabbit anti–GLP-1 (Peninsula), guinea pig anti-gastrin (Euro
Diagnostics), goat anti-ghrelin (Santa Cruz Biotechnology), rabbit anti-CCK
(Chemicon), rabbit anti-secretin, rabbit anti-substance P, rabbit anti-PYY,
rabbit anti-neuropeptide 4 (NPY), rabbit anti-serotonin (Euro-Diagnostica),
rabbit anti-somatostatin (Dako), and rabbit anti-Ipf1 (17). Secondary antibod-
ies used were Alexa 488 anti-goat, Alexa 488 anti–guinea pig, Alexa 594
anti–guinea pig, Alexa 594 anti-rabbit, Alexa 594 anti-goat (all from Molecular
Probe), Cy3 anti-rabbit, and ﬂuorescein isothiocyanate (FITC) anti-chicken
(The Jackson Laboratories). The gut hormone and Gpr40 expression analyses
were performed on 2- to 3-month-old mice. For the antibody cocktail
experiment, we made a two-step staining procedure: The tissue sections was
ﬁrst incubated with a mixture of antibodies directed against GIP, GLP-1,
ghrelin, CCK, and gastrin, and for these, the corresponding Alexa 594-
ﬂuorochrome secondary antibodies were used. Next, the tissue sections were
incubated with antibodies directed against -gal for which a FITC-conjugated
secondary antibody was used.
Cell counting. Pylorus and the three proximal centimetres of small intestine
corresponding to the duodenum and part of the jejunum were isolated from
wild-type, Gpr40
/lacZ, and Gpr40
lacZ/lacZ (n  3) nonfasted mice, ﬁxed in 4%
paraformaldehyde at 4°C for 1–2 h, cryoprotected in 30% sucrose at 4°C
overnight, frozen in Tissue-Tek (Sakura), and kept at 80°C. Three 8-m-thick
sections where collected on every slide with 160 m between sections. The
sections of pylorus/duodenum were stained with antibodies against GIP,
GLP-1, ghrelin, CCK, gastrin, PYY, secretin, serotonin, substance P, and -gal
and manually analyzed for distribution and colocalization of the different
markers. Colocalization between -gal and GLP-1 was also determined in the
distal 3 cm of the ileum, i.e., close to the appendix, in Gpr40
/lacZ mice.
Quantiﬁcation of mRNA expression levels. cDNA was prepared from total
RNA isolated from islets (18) and from e16 pylorus/duodenum and the distal
part of the ileum using NucleoSpin RNAII-kit (635990; Machery-Nagel) and
Super SMART PCR (635000; Clontech). Quantitative real-time PCR analysis
was performed using the ABI PRISM 7000 Sequence Detection System and SYBR
Green PCR Master Mix (ABI) according to the manufacturer’s recommendations.
Expression of the -2-microglobulin (2M), TATA-box–binding protein (TBP),
-actin, and glyceraldhyde-3-phosphate dehydrogenase (Gapdh) genes was used
to normalize expression levels. Primer sequences were as follows: -actin,
5-GCTCTGGCTCCTAGCACCAT-3 and 5-GCCACCGATCCACACAGAGT-3;
Gapdh,5 -CGTGTTCCTACCCCCAATGT-3 and 5-TGTCATCATACTTGGCAG
GTTTCT-3; 2M,5 -GCTATCCAGAAAACCCCTCAAA-3 and 5-CTGTGTTAC
GTAGCAGTTCAGTATGTTC-3;TBP,5 -GAATTGTACCGCAGCTTCAAAA-3and
5-AGTGCAATGGTCTTTAGGTCAAGTT; Ipf1/Pdx1,5 -TAGGACTCTTTCCTG
GGACCAA-3 and 5-AATAAAAAGGGTACAAACTTGAGCGT-3; and Gpr40,5 -
TTTCATAAACCCGGACCTAGGA-3 and 5-CCAGTGACCAGTGGGTTGAGT-3.
Statistical analyses were performed by an unpaired Student’s t test.
RESULTS
Gpr40 is expressed in cells of the gastrointestinal
tract. Gpr40 has been suggested to be expressed at other
sites than -cells, including in the intestine (1,11). How-
ever, these Gpr40 expression studies build on RT-PCR
analyses, and because the coding region of Gpr40 lacks an
intron, contaminating genomic DNA might give false pos-
itives in PCR analyses. To avoid such problems, we
previously made use of the lacZ reporter gene insertion
into the Gpr40 locus of targeted Gpr40
/lacZ mice and
showed that Gpr40 is not expressed in brain, liver, muscle,
or adipose tissue (2). We therefore extended our analyses
of Gpr40 expression using the Gpr40
/lacZ mice to eluci-
date whether Gpr40 is expressed in the gastrointestinal
tract. Distinct X-gal staining was evident in scattered
epithelial cells of the gastric pylorus, duodenum, jejunum,
ileum, and colon (Fig. 1A). The expression of Gpr40 in the
epithelium of the stomach and intestine was evident from
e14.5–e15 (data not shown), i.e., coincident with the
appearance of differentiated endocrine cells of the gastro-
intestinal tract. The expression of Gpr40 in pylorus and
duodenum was conﬁrmed by in situ hybridization analyses
using a Gpr40 riboprobe (Fig. 1B). Together, these data
demonstrate that Gpr40 is expressed in scattered cells
distributed throughout the gastrointestinal tract.
The Gpr40
 cells of the gastrointestinal tract repre-
sent enteroendocrine cells. To determine the identity of
the gastrointestinal cells expressing Gpr40, we next per-
formed double immunohistochemical analyses of the epi-
thelium of the gastric pylorus, duodenum, and ileum in
2- to 3-month-old mice using anti–-gal antibodies and
antibodies speciﬁc for different gastrointestinal hormones.
The -gal
, i.e., Gpr40
, cells were shown to express a
wide variety of endocrine hormones. In the pylorus and
duodenum, -gal/Gpr40 expression colocalized with gas-
trin, GIP, GLP-1, ghrelin, CCK, PYY, secretin, serotonin,
and substance P expression; and in the ileum, -gal/Gpr40
expression colocalized predominantly with that of GLP-1
(Fig. 1C; data not shown). In contrast, no coexpression of
-gal/Gpr40 and somatostatin or NPY was observed (data
not shown). The degree of -gal/Gpr40 expression varied
between 20 and 55% for the different gastrin, GIP, GLP-1,
ghrelin, CCK, PYY, secretin, and serotonin hormone-ex-
pressing cells (Table 1), and 	1% of the substance P
 cells
expressed -gal/Gpr40 (data not shown). However, immu-
nohistochemical analyses using a cocktail of gut hormone
antibodies, including GIP, GLP-1, ghrelin, CCK, and gastrin
and -gal antibodies, revealed that virtually all -gal/
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shown). The distribution and number of enteroendocrine
cells were normal in Gpr40
lacZ/lacZ mice (Table 2; data not
shown). Thus, Gpr40 is expressed both in insulin-produc-
ing -cells and hormone-producing cells of the gastroin-
testinal tract.
Impaired secretion of GIP and GLP-1 in Gpr40-null
mutants. GIP and GLP-1 hormones are secreted from the
intestinal K- and L-cells, respectively (19), and the secre-
tion of GIP and GLP-1 hormones can be stimulated both by
glucose and FFAs (20,21). The secretion of GLP-1 and GIP
hormones into the circulation positively inﬂuences insulin
FIG. 1. Gpr40 is expressed in gut enteroendocrine cells. A: X-gal staining of sections of pylorus, duodenum, jejunum, ileum, and colon in
2-month-old Gpr40
/ and Gpr40
/lacZ mice. B: In situ hybridization using Gpr40-speciﬁc probes on sections of neonatal epithelium in stomach
and duodenum. Arrows indicate cells expressing Gpr40 mRNA. C: Confocal sections of 2- to 3-month-old adult Gpr40
/lacZ pylorus and duodenum
stained with anti–-gal antibodies (green) to indicate Gpr40 expression and antibodies speciﬁc for the indicated enteroendocrine hormones
(red). (Please see http://dx.doi.org/10.2337/db08-0307 for a high-quality digital representation of this ﬁgure.)
TABLE 1
Coexpression of gut hormones and Gpr40
Gastrin GIP GLP-1 Ghrelin CCK PYY Secretin Serotonin
52 
 0.6 50 
 55 5 
 53 4 
 35 0 
 12 1 
 23 0 
 41 9 
 3
Data are percentage of hormone-expressing cells coexpressing -gal/Gpr40. Sections of pylorus (gastrin) and duodenum (GIP, GLP-1,
ghrelin, CCK, PYY, secretin, and serotonin) from 2- to 3-month-old Gpr40
/lacZ mice (n  3) were double stained for gut hormones and -gal.
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comparing oral and intravenous or intraperitoneal admin-
istration of glucose; oral glucose administration triggers a
more robust insulin secretory response (19). The expres-
sion of Gpr40 in both GIP-and GLP-1–expressing cells
leaves open the possibility that Gpr40 may affect insulin
secretion not only directly by virtue of its expression in
-cells, but also indirectly via regulation of incretin secre-
tion. Consistent with the FFA but not glucose responsive-
ness of Gpr40, no difference in glucose clearance rates or
insulin secretion was observed between Gpr40
lacZ/lacZ and
wild-type mice, regardless of whether glucose was admin-
istered orally or injected in the peritoneum (Fig. 2A–D).
We next explored the glucose and insulin response to
acute, oral administration of high-fat diet in Gpr40
lacZ/lacZ
and wild-type mice. Plasma levels of FFAs, triglycerides,
and glucagon were similar in oral high-fat diet–treated
Gpr40
lacZ/lacZ and wild-type mice (Supplementary Fig. 1
available in an online appendix at http://dx.doi.org/
10.2337/db08-0307). In contrast, plasma insulin levels were
reduced and blood glucose levels were increased at 60 min
in Gpr40
lacZ/lacZ compared with that of wild-type mice in
response to oral high-fat diet (Fig. 3A and B), suggesting
that incretin secretion in response to fat might be impaired
in Gpr40
lacZ/lacZ mice. Analyses of incretin levels after oral
high-fat diet showed that total plasma GIP levels were
reduced at 30 and 60 min and total plasma GLP-1 levels
were reduced at 60 min compared with that of wild types
(Fig. 3C and D). In contrast, no difference in total GIP or
GLP-1 levels were observed at 30 or 60 min after oral
glucose administration (Supplementary Fig. 2). Taken
together, these data provide evidence for a role for Gpr40
in FFA-mediated secretion of the incretins GIP and GLP-1.
Ipf1/Pdx1 is required for the expression of Gpr40 in
-cells. Recent data show that the transcription factor
IPF1/PDX1 can bind to an enhancer element within the
Gpr40 5-ﬂanking region (5), leaving open the possibility
that IPF1/PDX1 might regulate Gpr40 expression. Ipf1/
Pdx1-null mutant mice fail to form a pancreas and thus die
at the neonatal stage (16), precluding any analyses of a
role for IPF1/PDX1 in the regulation of Gpr40 expression
in -cells. We have, however, previously generated -cell–
TABLE 2
Gut hormone-expressing cells in Gpr40
lacZ/lacZ mice
GIP GLP-1 Ghrelin CCK Gastrin
Gpr40
/ 490 
 113 279 
 38 1,114 
 249 492 
 40 689 
 20
Gpr40
lacZ/lacZ 530 
 45 246 
 36 1,040 
 171 383 
 81 754 
 52
t test 0.63 0.18 0.29 0.87 0.46
Data are n. Hormone-expressing cells were counted on sections from pylorus (gastrin) and duodenum (GIP, GLP-1, ghrelin, and CCK) in 2-
to 3-month-old Gpr40
/ (n  3) and Gpr40
lacZ/lacZ (n  3) mice.
FIG. 2. Oral glucose tolerance is normal in Gpr40
lacZ/lacZ mice. Blood glucose (A and B) and plasma insulin (C and D) levels in 2- to 3-month-old
Gpr40
/ () and Gpr40
lacZ/lacZ (Œ) mice after intraperitoneal glucose injections (A and C) and oral glucose administration (B and D). Gpr40
/
(n  16) and Gpr40
lacZ/lacZ (n  16) for the intraperitoneal glucose injections. Gpr40
/ (n  6) and Gpr40
lacZ/lacZ (n  5) for the oral glucose
administration test.
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 mice, using
the Cre-LoxP system (12). The conditional inactivation of
Ipf1/Pdx1 in -cells of RIP/Ipf1
 mice results in -cell
dysfunction due to reduced expression of key -cell
components, including insulin, glucose transporter type 2,
and PC1/3, and the mice consequently show severely
impaired insulin secretion and develop diabetes (12). To
elucidate whether Gpr40 expression was regulated by
Ipf1/Pdx1 in adult -cells, we bred the Gpr40
/lacZ allele
into the RIP/Ipf1
 background. The Gpr40
/lacZ mice
carry the lacZ gene targeted into the Gpr40 locus, thus
allowing monitoring of Gpr40 expression by X-gal stain-
ing. In RIP/Ipf1
 mice, the conditional inactivation of the
Ipf1/Pdx1 gene in -cells occurs progressively after birth,
and the mice develop overt diabetes when Ipf1/Pdx1 has
been inactivated in 80% of the -cells (12).
In 5-week-old Ipf1/Pdx1
/;Gpr40
/lacZ control mice,
strong, uniform X-gal staining was observed in the -cells
(Fig. 4A). In contrast, the majority of the -cells in islets of
age-matched, glucose-intolerant but not overt diabetic
RIP/Ipf1
;Gpr40
/lacZ mice were X-gal
, providing evi-
dence that conditional inactivation of Ipf1/Pdx1 in -cells
results in a loss of Gpr40 expression (Fig. 4A). Quantita-
tive RT-PCR of cDNA prepared from islets conﬁrmed the
decreased expression of Gpr40 in -cells of RIP/Ipf1

mice and showed that Gpr40 expression was reduced to a
similar extent to that of Ipf1/Pdx1 in isolated islets (Fig.
4B). Together, these data provide evidence that Ipf1/Pdx1
(directly or indirectly) is required for Gpr40 expression in
-cells.
Gpr40 expression in endocrine cells of the anterior
gastrointestinal tract requires Ipf1/Pdx1. Apart from
-cells, IPF1/PDX1 is expressed also in hormone-produc-
ing cells of the gastric pylorus and duodenum, where it has
been shown to be required for the expression of several
hormones (22). The similar expression proﬁles observed
for IPF1/PDX1 and Gpr40 raised the possibility that the
expression of Gpr40 in endocrine cells of the anterior
gastrointestinal tract, like that in -cells, is dependent on
Ipf1/Pdx1. To explore a potential role for IPF1/PDX1 in
regulating Gpr40 expression, we bred the Gpr40
/lacZ
allele into the Ipf1/Pdx1-null mutant (16) background and
analyzed the intestinal expression of Gpr40 by X-gal
staining. Because Ipf1/Pdx1-null mutants die at the neo-
natal stage, Gpr40 expression analyses were performed on
late-stage, embryonic gastrointestinal tissue. In contrast to
control Ipf1/Pdx1
/;Gpr40
/lacz mice, no X-gal
, i.e.,
Gpr40-expressing, cells were observed in the gastric py-
lorus and duodenum of Ipf1/Pdx1
/;Gpr40
/lacz embryos
(Fig. 5A). Quantitative RT-PCR on cDNA isolated from the
gastric pylorus and duodenum of wild-type and Ipf1/
Pdx1
/ embryos conﬁrmed that expression of Gpr40 in
these regions of the gastrointestinal tract is dependent on
Ipf1/Pdx1 (Fig. 5B). In the more distal regions of gastro-
intestinal tract, including the ileum, where IPF1/PDX1 is
not expressed, -gal/Gpr40 expression was unaffected in
Ipf1/Pdx1-null mice (data not shown). Together, these
data provide evidence for a conserved role for Ipf1/Pdx1
in regulating Gpr40 expression in pancreatic -cells and
endocrine cells of the gastric pylorus and duodenum.
DISCUSSION
The FFA-responsive G-protein–coupled receptor Gpr40 is
expressed in pancreatic -cells where it contributes to
FFA-mediated enhancement of glucose-induced insulin
secretion (1–4), and Gpr40 mutant mice do not develop
hyperinsulinemia on a high-fat diet (2). Here, we show that
Gpr40 is expressed also in hormone-producing cells of the
gastrointestinal tract, including GIP
 and GLP-1
 cells.
FFAs are known to stimulate the secretion of both GIP and
GLP-1 incretin hormones (20,21), and other G-protein–
FIG. 3. Reduced plasma levels of GIP and GLP-1 in Gpr40
lacZ/lacZ mice in response to fat diet. Plasma insulin, GIP (total), GLP-1 (total), and blood
glucose levels (A–D) were determined in 2- to 3-month-old Gpr40
/ (n  10–16, ) and Gpr40
lacZ/lacZ (n  8–20, u) mice after oral high-fat diet
administration. x-axis indicates minutes after oral gavage. Data are means  SE. *P < 0.05 for Gpr40
/ vs. Gpr40
lacZ/lacZ.
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implicated in the secretion of incretin hormones (9,10).
Activation of Gpr120 by -linolenic acid, docosahexaoi-
enic, or palmitoleic acid in STC-1 cells promoted GLP-1
secretion (9), and upon an oral load of the Gpr119 agonist
AR231453, plasma concentrations of GLP-1 and GIP in-
creased in control animals but not in Gpr119-deﬁcient
mice (10). In this study, we found that Gpr40-null mice
show impaired secretion of both GIP and GLP-1 in re-
sponse to acute, oral fat diet administration with a con-
comitant reduction in insulin secretion and glucose
clearance. Together, these ﬁndings provide evidence for a
role for Gpr40 in FFA stimulation of incretin secretion.
The expression of Gpr40 in endocrine cells of gastrointes-
tinal tract leaves open the possibility that Gpr40, as a
component of the entero-insular axis, may regulate insulin
secretion in response to fatty acids at several levels. Thus,
apart from directly inﬂuencing insulin secretion from
-cells via circulating FFAs, Gpr40 may indirectly stimu-
late GSIS from -cells by modulating the secretion of the
incretin hormones GIP and GLP-1 in response to FFAs
present in the gastrointestinal lumen (23,24).
The gut hormones ghrelin and CCK play important and
opposing roles in regulating food intake; ghrelin is consid-
ered to be an appetite hormone, and CCK a satiety
hormone. The release of these two hormones is regulated
by food intake, especially fat. Ghrelin levels in blood
circulation are reduced by long-chain fatty acids (25),
whereas CCK levels are increased by medium- to long-
chain fatty acids (26). However, Gpr40 mutant mice show
a normal growth rate on both control and high-fat diet and
do not present with any apparent signs of perturbed food
intake patterns (2,4). Ghrelin has also been suggested to
inﬂuence insulin secretion, but the data are conﬂicting;
both stimulatory and inhibitory effects on insulin secretion
have been reported (27–31). The role, if any, for Gpr40 in
FIG. 4. Gpr40 expression in -cells cells requires Ipf1/Pdx1. A: X-gal–
stained sections (top panel) of 5-week-old adult islets from Ipf1/
Pdx1
/;Gpr40
/lacZ and RIP/Ipf1
;Gpr40
/lacZ mice counterstained
with anti-insulin antibodies (bottom panel). B: Quantitative real-time
RT-PCR expression analyses of islet cDNA from Ipf1/Pdx1
/ (, n 
4) and RIP/Ipf1
 (u, n  6) mice. Data are means  SE. *P < 0.05 for
Ipf1/Pdx1
/ vs. RIP/Ipf1
 islets.
FIG. 5. Gpr40 expression in enteroendocrine cells requires Ipf1/Pdx1.
A: X-gal–stained sections of the pyloric sphincter and in duodenum of
e17 Ipf1/Pdx1
/;Gpr40
/lacZ and Ipf1/Pdx1
/;Gpr40
/lacZ embryos. B:
Quantitative real-time RT-PCR expression analysis of cDNA isolated
from pylorus/duodenum of Ipf1/Pdx1
/ (, n  3) and Ipf1/Pdx1
/
embryos (u, n  3). Data are means  SE. *P < 0.05 and ***P < 0.001
for Ipf1/Pdx1
/ vs. Ipf1/Pdx1
/. Brackets in A indicate the border of
the smooth muscle layer surrounding the lumen of the gut tube. sto.,
stomach; int., intestine.
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FFAs will have to await future analyses.
In -cells, IPF1/PDX1 regulates the expression of sev-
eral genes that ultimately ensure proper GSIS and thus
-cell function (12–14,17). Relatively little is known about
the regulation of Gpr40 expression in -cells. A recent
study suggests, however, that IPF1/PDX1 and the basic-
helix-loop-helix transcription factor NeuroD/2, which
also is expressed in -cells, bind to an enhancer element
within the 5-ﬂanking region of Gpr40 (5). Here, we show
in vivo that loss of Ipf1/Pdx1 in -cells impairs Gpr40
expression, providing evidence not only that IPF1/PDX1
can bind to the Gpr40 5-ﬂanking region (5) but that
IPF1/PDX1 is required for Gpr40 expression in -cells.
IPF1/PDX1 is expressed also in endocrine cells of the
gastric pyloric antrum and duodenum (22,32). In Ipf1/
Pdx1-null mutant mice, the expression proﬁle of several
gut hormones is changed; fewer gastrin
 but more sero-
tonin
 cells were, for example, observed in the antrum of
these mice (22). In this study, we show that the expression
of Gpr40 in endocrine cells of the anterior gastrointestinal
tract is lost in Ipf1/Pdx1
/ mice. Thus, like Ipf1/Pdx1,
Gpr40 is expressed in both -cells and endocrine cells of
the anterior gastrointestinal tract, and Ipf1/Pdx1 function
is essential for Gpr40 expression in both of these cell
types. Taken together, these data suggest a conserved role
for Ipf1/Pdx1 in cells that secrete hormones in response to
food intake. However, IPF1/PDX1 is not expressed in the
more distal part of the gastrointestinal tract, and Gpr40
expression at these sites is not affected in Ipf1/Pdx1-null
mice. Thus, Gpr40 expression in posterior enteroendo-
crine cells is Ipf1/Pdx1 independent. However, the identity
of transcription factors regulating Gpr40 expression in
endocrine cells of the posterior gastrointestinal tract re-
mains unknown.
Like other cells of the gastrointestinal epithelium, en-
teroendocrine cells undergo constant renewal involving
stem cell division, differentiation, and cell death. Gpr40

cells are more abundant in the gastric pyloric antrum and
duodenum than in the more posterior ileum and colon. In
the gastric pyloric antrum, Gpr40 is predominantly ex-
pressed in gastrin
 cells close to the crypts of pyloric pits.
In the intestine, Gpr40 expression was evident in endo-
crine cells expressing ghrelin, GIP, GLP-1, CCK, PYY,
substance P, serotonin, and secretin. Although virtually all
Gpr40-expressing cells were hormone positive, only 20–
55% of the individual hormone expressing cells also ex-
pressed Gpr40. Whether this reﬂects the maturation
process of the cycling enteroendocrine cells, i.e., that
Gpr40 is expressed only at a speciﬁc stage of differentia-
tion or that only a subpopulation of the individual en-
teroendocrine cells expresses Gpr40, which in turn would
indicate functional differences, remains an open question.
By virtue of its contribution to FFA-enhanced insulin
secretion from -cells, GPR40 is a link between obesity
and type 2 diabetes. FFA stimulation of insulin secretion
from -cells is reduced in Gpr40 mutant mice, and these
mice do not develop hyperinsulinemia on a high-fat diet
(2). The expression of Gpr40 in GLP-1
 and GIP
 cells
and the impaired secretion of these hormones in Gpr40-
null mice in response to acute, oral fat diet leaves open the
possibility that the difference in insulin levels in control
and Gpr40-null mice on high-fat diet results from com-
bined direct, i.e., -cells, and indirect, i.e., incretin cells,
effects of FFA on insulin secretion. The expression of
Gpr40 in endocrine cells expressing hormones that con-
trol food intake is suggestive of a role for Gpr40 in the
secretion of also these hormones. Increased knowledge of
the role for Gpr40 in -cells and endocrine cells of the
gastrointestinal tract may therefore be of great therapeutic
relevance not only for obesity-associated diabetes but also
for obesity itself but will have to await the generation of
-cell– and enteroendocrine cell–speciﬁc Gpr40 mutant
mice.
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